(19)
(11) EP 4 581 166 A1

(12)

(43) Date of publication:
09.07.2025 Bulletin 2025/28

(21) Application number: 23761162.9

(22) Date of filing: 29.08.2023
(51) International Patent Classification (IPC): 
C12Q 1/6886(2018.01)
G01N 33/574(2006.01)
(52) Cooperative Patent Classification (CPC):
C12Q 1/6886; C12Q 2600/158; C12Q 2600/118; C12Q 2600/106
(86) International application number:
PCT/EP2023/073583
(87) International publication number:
WO 2024/047001 (07.03.2024 Gazette 2024/10)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 31.08.2022 US 202217900049
24.10.2022 EP 22203263

(71) Applicant: Indivumed GmbH
20251 Hamburg (DE)

(72) Inventors:
  • WELLSTEIN, Anton
    Washington, DC 20007 (US)
  • WOODSMITH, Jonathan
    22309 Hamburg (DE)

(74) Representative: Zellentin & Partner mbB Patentanwälte 
Rubensstraße 30
67061 Ludwigshafen
67061 Ludwigshafen (DE)

   


(54) CHRM3 AS A MARKER AND TARGET FOR COLON CANCER THERAPY